VitD significantly attenuated L-DOPA-induced abnormal involuntary movements (AIMs) in a mouse model of PD, showing a maximal reduction of 32.7% on day 14 of treatment without altering dopamine metabolic enzymes such as TH and MAO-B. This evidence concerns the gene MAOB and Parkinson disease.